Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2023-04-26 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于公司药品利福平胶囊通过一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a pharmaceutical product (Rifampin Capsules) passing a consistency evaluation by the National Medical Products Administration. It includes details about the drug, its uses, and the impact on the company. The document is short (1169 characters) and does not contain financial statements, management discussion, or detailed financial data. It is an official announcement about a regulatory approval related to the company's product, not a financial report or earnings release. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a regulatory announcement about product approval and its impact, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-04-26 Chinese
关于提请股东大会授权董事会办理以简易程序向特定对象发行股票的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding a proposal to the shareholders' meeting to authorize the board of directors to issue shares to specific investors through a simplified procedure. It details the terms of the proposed share issuance, including the amount, pricing, lock-up period, and authorization scope. The document references the need for shareholder approval at the 2022 annual general meeting and includes legal and regulatory compliance statements. It does not contain actual financial statements or results but is a formal notice about a capital raising proposal requiring shareholder approval. This fits the category of a Capital/Financing Update (CAP) rather than a full report or regulatory filing. The document length is under 5,000 characters, but it is not merely announcing the publication of a report; it is an announcement of a financing proposal and authorization request.
2023-04-25 Chinese
独立董事年度述职报告
Governance Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2022 from a specific company. It details the independent director's attendance at board and shareholder meetings, opinions on various board matters, committee work, investigations, supervision of information disclosure, governance, and shareholder rights protection. It is a narrative report on the independent director's activities and opinions rather than a financial report or announcement. The document length is 3412 characters, which is relatively short and does not contain financial statements or data. It is not an announcement of voting results, management changes, or legal proceedings. It is a governance-related report focusing on the independent director's role and oversight. Therefore, the best fitting category is Governance Information (CGR).
2023-04-25 Chinese
独立董事对担保等事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on various matters related to the company for the fiscal year 2022, including related party transactions, external guarantees, profit distribution and capital reserve conversion plans, fundraising usage, internal control evaluation, credit facilities, and a proposal for a simplified stock issuance. It references compliance with regulatory guidelines and company bylaws, and it is dated April 25, 2023. The document is a formal opinion letter from independent directors rather than a full financial report or earnings release. It does not contain comprehensive financial statements or detailed financial analysis but rather assessments and approvals of specific corporate governance and financial matters. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory compliance-related disclosure and independent opinion rather than a full report or announcement of voting results or management changes.
2023-04-25 Chinese
2022年年度财务报告
Annual Report Classification · 100% confidence The document is titled as the 2022 annual financial report of Teyi Pharmaceutical Group Co., Ltd. It contains an audit report with an unqualified opinion, detailed financial statements including consolidated and parent company balance sheets, income statements, and cash flow statements for the year ended December 31, 2022. The presence of comprehensive financial data, audit opinions, and notes indicates this is a full annual report. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, it fits the definition of an Annual Report (10-K). FY 2022
2023-04-25 Chinese
内部控制审计报告
Regulatory Filings
2023-04-25 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.